02/14/2025
7:01 PM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
Redmile Group, LLC (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
10:34 AM | JANUS HENDERSON GROUP PLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SCHEDULE 13G/A | |
02/14/2025
8:00 AM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025
6:30 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/18/2024
3:01 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 424B3 | |
12/16/2024
11:15 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form EFFECT | |
12/11/2024
3:05 PM | COMMODORE CAPITAL LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G | |
12/02/2024
4:27 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
11/27/2024
3:36 PM | AKKARAJU SRINIVAS (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Samsara BioCapital GP, LLC (Reporting)
Samsara BioCapital, L.P. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
11/25/2024
8:29 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/25/2024
8:29 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for NLTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
11/21/2024
3:01 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/18/2024
4:26 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/18/2024
4:27 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/18/2024
5:50 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
3:53 PM | GREAT POINT PARTNERS LLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
11/14/2024
2:24 PM | JANUS HENDERSON GROUP PLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
11/14/2024
2:05 PM | Cormorant Asset Management, LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
11/14/2024
5:22 AM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SC 13G | |
11/04/2024
6:33 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/09/2024
3:15 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/09/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/07/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/08/2024
3:36 PM | BlackRock Inc. (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G | |
06/21/2024
7:32 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/18/2024
1:11 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
1:35 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
1:35 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:36 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Noonberg Sarah B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:36 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:37 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
PALEKAR ROHAN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:37 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Woods Robert Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/10/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2024
5:20 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form DEF 14A | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form ARS | |
04/26/2024
1:34 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form DEFA14A | |
04/22/2024
3:44 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/02/2024
2:43 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/14/2024
7:51 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Buy this AI Stock Before Elon’s Announcement (Ad) With Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dust.
This isn't just a prediction; it's a calculated shift backed by political support, policy changes, and Musk's proven track record.
I've identified a company that is quietly enabling xAI's rapid growth. Click here to watch my presentation and learn how to invest today. |
03/14/2024
7:53 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/14/2024
7:54 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
3:29 PM | Babler Martin (Reporting)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
5:20 PM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
Smith Sean Michael (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
6:30 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
